ESR1 and cancer: Basal A, also called “basal” cancers (ER-, PR-, HER2-) have high Ki67 expression, typically express epidermal growth factor receptor (EGFR+) and/or cytokeratin 5/6, and frequently respond to chemotherapy [10].